Format

Send to

Choose Destination
Pancreatology. 2016 Jul-Aug;16(4):584-92. doi: 10.1016/j.pan.2016.03.013. Epub 2016 Mar 30.

Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.

Author information

1
Vejle Hospital, Southern Denmark, Odense, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark. Electronic address: maiken.t.joergensen@rsyd.dk.
2
Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark.
3
Centre for Health Economic Research (COHERE), Institute of Public Health, University of Southern Denmark, Odense, Denmark.
4
Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
5
Department of Surgery, Odense University Hospital, Odense, Denmark.

Abstract

OBJECTIVE:

Pancreatic cancer (PC) is the fourth leading cause of cancer death worldwide, symptoms are few and diffuse, and when the diagnosis has been made only 10-15% would benefit from resection. Surgery is the only potentially curable treatment for pancreatic cancer, and the prognosis seems to improve with early detection. A hereditary component has been identified in 1-10% of the PC cases. To comply with this, screening for PC in high-risk groups with a genetic disposition for PC has been recommended in research settings.

DESIGN:

Between January 2006 and February 2014 31 patients with Hereditary pancreatitis or with a disposition of HP and 40 first-degree relatives of patients with Familial Pancreatic Cancer (FPC) were screened for development of Pancreatic Ductal Adenocarcinoma (PDAC) with yearly endoscopic ultrasound. The cost-effectiveness of screening in comparison with no-screening was assessed by the incremental cost-utility ratio (ICER).

RESULTS:

By screening the FPC group we identified 2 patients with PDAC who were treated by total pancreatectomy. One patient is still alive, while the other died after 7 months due to cardiac surgery complications. Stratified analysis of patients with HP and FPC provided ICERs of 47,156 US$ vs. 35,493 US$ per life-year and 58,647 US$ vs. 47,867 US$ per QALY. Including only PDAC related death changed the ICER to 31,722 US$ per life-year and 42,128 US$ per QALY. The ICER for patients with FPC was estimated at 28,834 US$ per life-year and 38,785 US$ per QALY.

CONCLUSIONS:

With a threshold value of 50,000 US$ per QALY this screening program appears to constitute a cost-effective intervention although screening of HP patients appears to be less cost-effective than FPC patients.

KEYWORDS:

Cost-utility analysis (CUA); Familial pancreatic cancer (FPC); Hereditary pancreatitis (HP); Incremental cost-effectiveness ratios (ICER); Quality-adjusted life-years (QALY); Screening

PMID:
27090585
DOI:
10.1016/j.pan.2016.03.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center